Yifan Yang

Yifan Yang

Auto-generated profile, based on publicly available information

Yifan Yang

Penn Cardiovascular Institute (D.C., M.B., J.A.B., I.M.-P., J.Y., Y.Y., M.P.M., T.G.D., S. Day, M.L., S. Damrauer, X.W., T.P.C.), University of Pennsylvania Perelman School of Medicine, Philadelphia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in Science
Verified
Journal Article
Closed access
BGBridget S. Gosis
Bridget S. Gosis
SWShogo Wada
Shogo Wada
CTChelsea Thorsheim
Chelsea Thorsheim
KLKristina Li
Kristina Li
SJSunhee Jung
Sunhee Jung
ZAZoltan Arany
Zoltan Arany
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) pathway is a potential therapeutic target, but conflicting interpretations have been proposed for how mTORC1 controls lipid homeostasis. We show that selective inhibition of mTORC1 signaling in mice, through deletion of the RagC/D guanosine triphosphatase–activating protein folliculin (FLCN), promotes activation of transcription factor E3 (TFE3) in the liver without affecting other mTORC1 targets and protects against NAFLD and NASH. Disease protection is mediated by TFE3, which both induces lipid consumption and suppresses anabolic lipogenesis. TFE3 inhibits lipogenesis by suppressing proteolytic processing and activation of sterol regulatory element–binding protein-1c (SREBP-1c) and by interacting with SREBP-1c on chromatin. Our data reconcile previously conflicting studies and identify selective inhibition of mTORC1 as a potential approach to treat NASH and NAFLD.

3 November 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
QMQuentin McAfee
Quentin McAfee
CCChristina Yingxian Chen
Christina Yingxian Chen
YYYifan Yang
Yifan Yang
MCMatthew A. Caporizzo
Matthew A. Caporizzo
MMMichael Morley
Michael Morley
ZAZolt Arany
Zolt Arany
Truncating mutations in TTN result in both truncated titin proteins and reduced full-length titin in patient hearts.

15 December 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
BKBoa Kim
Boa Kim
WZWencao Zhao
Wencao Zhao
STSoon Y. Tang
Soon Y. Tang
MLMichael G. Levin
Michael G. Levin
AIAyon Ibrahim
Ayon Ibrahim
ZAZoltan Arany
Zoltan Arany
Metabolic syndrome, today affecting more than 20% of the US population, is a group of 5 conditions that often coexist and that strongly predispose to cardiovascular disease. How these conditions are linked mechanistically remains unclear, especially two of these: obesity and elevated blood pressure. Here, we show that high fat consumption in mice leads to the accumulation of lipid droplets in endothelial cells throughout the organism and that lipid droplet accumulation in endothelium suppresses endothelial nitric oxide synthase (eNOS), reduces NO production, elevates blood pressure, and accelerates atherosclerosis. Mechanistically, the accumulation of lipid droplets destabilizes eNOS mRNA and activates an endothelial inflammatory signaling cascade that suppresses eNOS and NO production. Pharmacological prevention of lipid droplet formation reverses the suppression of NO production in cell culture and in vivo and blunts blood pressure elevation in response to a high-fat diet. These results highlight lipid droplets as a critical and unappreciated component of endothelial cell biology, explain how lipids increase blood pressure acutely, and provide a mechanistic account for the epidemiological link between obesity and elevated blood pressure.

14 December 2020 in eLife
Verified
Journal Article
Open access
NYNora Yucel
Nora Yucel
JAJessie Axsom
Jessie Axsom
YYYifan Yang
Yifan Yang
LLLi Li
Li Li
JRJoshua H Rhoades
Joshua H Rhoades
ZAZoltan Arany
Zoltan Arany
Endothelial cells (ECs) are widely heterogenous depending on tissue and vascular localization. Jambusaria et al. recently demonstrated that ECs in various tissues surprisingly possess mRNA signatures of their underlying parenchyma. The mechanism underlying this observation remains unexplained, and could include mRNA contamination during cell isolation, in vivo mRNA paracrine transfer from parenchymal cells to ECs, or cell-autonomous expression of these mRNAs in ECs. Here, we use a combination of bulk RNASeq, single-cell RNASeq datasets, in situ mRNA hybridization, and most importantly ATAC-Seq of FACS-isolated nuclei, to show that cardiac ECs actively express cardiomyocyte myofibril (CMF) genes and have open chromatin at CMF gene promoters. These open chromatin sites are enriched for sites targeted by cardiac transcription factors, and closed upon expansion of ECs in culture. Together, these data demonstrate unambiguously that the expression of CMF genes in ECs is cell-autonomous, and not simply a result of technical contamination or paracrine transfers of mRNAs, and indicate that local cues in the heart in vivo unexpectedly maintain fully open chromatin in ECs at genes previously thought limited to cardiomyocytes.

15 September 2020 in Journal of the Chinese Medical Association
Verified
Journal Article
Open access
TYTzu-Han Yang
Tzu-Han Yang
CCChian-Ying Chou
Chian-Ying Chou
YYYi-Fan Yang
Yi-Fan Yang
CCChianshiu Chien
Chianshiu Chien
AYAliaksandr A Yarmishyn
Aliaksandr A Yarmishyn
YCYuh-Lih Chang
Yuh-Lih Chang
Background: Since COVID-19 outbreak, hydroxychloroquine (HCQ) has been tested for effective therapies, and the relevant researches have shown controversial results. Methods: Systematic review and meta-analysis were conducted after a thorough search of relevant studies from databases. Trials that have evaluated HCQ for COVID-19 treatment were recruited for statistical analysis with fixed- and random-effect models. Results: Nine trials involving 4112 patients were included in present meta-analysis. It was seen that HCQ-azithromycin (HCQ-AZI) combination regimen increased the mortality rate in COVID-19 (odds ratio [OR], 2.34; 95% confidence interval [CI], 1.63–3.36) patients; however, it also showed benefits associated with the viral clearance in patients (OR, 27.18; 95% CI, 1.29–574.32). HCQ-alone when used as a therapy in COVID-19 did not reveal significant changes in mortality rate, clinical progression, viral clearance, and cardiac QT prolongation. Subsequent subgroup analysis showed that HCQ treatment could decrease mortality rate and progression to severe illness in severely infected COVID-19 patients (OR, 0.27; 95% CI, 0.13–0.58). A lower risk of mortality rate was also noted in the stratified group of >14 days follow-up period (OR, 0.27; 95% CI, 0.13–0.58) compared to ≤14 days follow-up period group that conversely showed an increased mortality rate (OR, 2.09; 95% CI, 1.41–3.10). Conclusion: Our results indicated that HCQ-AZI combination treatment increased mortality rate in patients with COVID-19, but it also showed benefits associated with viral clearance in patients. HCQ-alone used for treatment has revealed benefits in decreasing the mortality rate among severely infected COVID-19 group and showed potential to be used for COVID-19 treatment in long-term follow-up period group. Accordingly, more rigorous, large-scale, and long follow-up period studies in patients with COVID-19 are needed.

12 November 2024 in Circulation
Verified
Journal Article
Closed access
DCDongwook Choe
Dongwook Choe
MBMegan Burke
Megan Burke
JBJeffrey A. Brandimarto
Jeffrey A. Brandimarto
IMIngrid Marti-Pamies
Ingrid Marti-Pamies
JYJaime Yob
Jaime Yob
TCThomas P. Cappola
Thomas P. Cappola